NASDAQ$BCYC
Bicycle Therapeutics plc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Bicycle Therapeutics reported Q4 2025 revenue of $48.0M from collaborations.
Collaboration revenue was $48.0 million in the quarter as partnered oncology programs advanced with large pharma collaborators.
- Q4 collaboration revenue $48.0M.
- Bicycle conjugate pipeline.
- Partnership milestones and R&D.
- Cash and operating loss.
Headline financials
Revenue & EPS history
Bicycle · Revenue · Quarterly
$48M
Forward guidance
The filing discusses operating priorities, liquidity, and sector risks; quantitative multi-quarter guidance varies by issuer.
Tailwinds
- MD&A highlights cash, capital, and core trends.
- Segment or product commentary supports the narrative.
Headwinds
- Macro or input costs may pressure margins.
- One-time items affect comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+1.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+19.3%
Q4 2019
Best reaction
-10.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +3.6% | -0.8% | |
| Q4 2025 | -4.2% | -13.9% | +1.8% | |
| Q3 2025 | +6.7% | -16.0% | -8.6% | |
| Q1 2025 | +6.1% | -13.6% | -4.0% | |
| Q4 2024 | -1.3% | -2.5% | -18.3% | |
| Q3 2024 | -5.5% | -2.2% | -15.1% | |
| Q2 2024 | -0.7% | +2.1% | -10.0% | |
| Q1 2024 | +1.6% | -4.6% | -8.3% | |
| Q4 2023 | +3.1% | +9.5% | +14.9% | |
| Q3 2023 | +1.2% | -0.7% | -2.3% | |
| Q2 2023 | +1.3% | -2.8% | -4.1% | |
| Q1 2023 | -0.4% | +2.5% | +15.7% | |
| Q4 2022 | -1.9% | -5.5% | -6.2% | |
| Q3 2022 | -3.2% | +0.8% | +29.6% | |
| Q2 2022 | +14.8% | +17.7% | +12.8% | |
| Q1 2022 | -10.8% | -22.6% | -33.6% | |
| Q4 2021 | -1.2% | -9.7% | -7.6% | |
| Q3 2021 | +0.7% | +2.5% | -6.8% | |
| Q2 2021 | +1.8% | +2.3% | +36.0% | |
| Q1 2021 | +1.9% | -1.3% | -5.5% | |
| Q4 2020 | +1.9% | +2.0% | +3.8% | |
| Q3 2020 | -1.5% | +3.1% | +5.2% | |
| Q2 2020 | -0.2% | +0.0% | +5.8% | |
| Q1 2020 | +0.7% | +6.6% | +23.2% | |
| Q4 2019 | +19.3% | +1.5% | -2.3% | |
| Q3 2019 | -4.2% | -7.7% | -4.8% | |
| Q2 2019 | +5.9% | +5.4% | -6.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro